Download fulltext
HTML
1.
Ghasemi H, Djalilian A. Topical Calcineurin Inhibitors: Expanding Indications for Corneal and Ocular Surface Inflammation. JOVR [Internet]. 2019Oct.24 [cited 2024Apr.23];14(4):398–399. Available from: https://knepublishing.com/index.php/JOVR/article/view/5435
https://doi.org/10.18502/jovr.v14i4.5435
statistics
- 729 Abstract Views
- 407 PDF Views
- 0 HTML Views
- Cited by 1 article
authors
-
Hamed Ghasemi
Hamed Ghasemi
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
-
Ali Djalilian
Ali Djalilian
University of Illinois at Chicago, USA
Published Date
- Oct 24, 2019
Topical Calcineurin Inhibitors: Expanding Indications for Corneal and Ocular Surface Inflammation
Abstract
This is an Editorial and does not have an abstract.
Keywords:
NA
References
1. Lee YJ, Kim SW, Seo KY. Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. Am J Ophthalmol 2013;155:804–813.
2. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008;115:988–992.
3. Ghaffari R, Ghassemi H, Zarei-Ghanavati M, Latifi G, Dehghani S, Haq Z, et al. Tacrolimus eye drops as adjunct therapy in severe corneal endothelial rejection refractory to corticosteroids. Cornea 2017;36:1195–1199.
4. Hashemian MN, Latifi G, Ghaffari R, Ghassemi H, Zarei- Ghanavati M, Mohammadi SF, et al. Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial. Cornea 2018;37:307–312.
5. Kheirkhah A, Zavareh M, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond) 2011;25:872–880.
6. Akbari A, Soltani Moghadam R, Elmi R, Nosrati A, Taghiabadi E, Aghdami, N. Topical Tacrolimus as an adjunct to conventional therapy for herpetic stromal keratitis: a randomized clinical trial. J Ophthalmic Vis Res 2019;14.
7. Chatterjee A, Bandyopadhyay S, Bandyopadhyay SK. Efficacy, safety, and steroid sparing effect of topical cyclosporine a 0.05% in vernal keratoconjunctivitis in Indian children. J Ophthalmic Vis Res 2019;14.
2. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008;115:988–992.
3. Ghaffari R, Ghassemi H, Zarei-Ghanavati M, Latifi G, Dehghani S, Haq Z, et al. Tacrolimus eye drops as adjunct therapy in severe corneal endothelial rejection refractory to corticosteroids. Cornea 2017;36:1195–1199.
4. Hashemian MN, Latifi G, Ghaffari R, Ghassemi H, Zarei- Ghanavati M, Mohammadi SF, et al. Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial. Cornea 2018;37:307–312.
5. Kheirkhah A, Zavareh M, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond) 2011;25:872–880.
6. Akbari A, Soltani Moghadam R, Elmi R, Nosrati A, Taghiabadi E, Aghdami, N. Topical Tacrolimus as an adjunct to conventional therapy for herpetic stromal keratitis: a randomized clinical trial. J Ophthalmic Vis Res 2019;14.
7. Chatterjee A, Bandyopadhyay S, Bandyopadhyay SK. Efficacy, safety, and steroid sparing effect of topical cyclosporine a 0.05% in vernal keratoconjunctivitis in Indian children. J Ophthalmic Vis Res 2019;14.